The ablation of Pgrmc2 clearly attenuated the incidence/development, progression, and aggressiveness of Pten loss-of-function-induced endometrial cancer by inhibiting endometrial glandular epithelial cell proliferation (Figure 6). This evidence concerns the gene PTEN and endometrial cancer.